Postes actifs de Johan Van Hoof
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
P.J.A. Beheer
 P.J.A. Beheer Financial ConglomeratesFinance P.J.A. Beheer is an investment holding Belgian company. The private company was founded in 2003. Johan Van Hoof has been the CEO of the company since 2017. | Directeur/Membre du Conseil | 01/10/2017 | - |
| Directeur Général | 01/10/2017 | - | |
Ziphius Vaccines NV
 Ziphius Vaccines NV BiotechnologyHealth Technology Ziphius Vaccines NV is a Belgian biopharmaceutical company that specializes in developing vaccines and therapeutics using its proprietary self-amplifying RNA and carrier technology platforms. The private company is based in Ghent, Belgium and has a portfolio of next-generation vaccine candidates that target infectious diseases and gene supplementation therapies. The company's lead compound, Zip1642, is a COVID-19 vaccine candidate that has undergone preclinical studies. The company was founded in 2019 by Christian Cardon, who has been the CEO since then. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Johan Van Hoof
Statistiques
Internationale
| Belgique | 3 |
Opérationnelle
| Director/Board Member | 2 |
| Chief Executive Officer | 1 |
Sectorielle
| Finance | 2 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
P.J.A. Beheer
P.J.A. Beheer Financial ConglomeratesFinance P.J.A. Beheer is an investment holding Belgian company. The private company was founded in 2003. Johan Van Hoof has been the CEO of the company since 2017. | Finance |
Ziphius Vaccines NV
Ziphius Vaccines NV BiotechnologyHealth Technology Ziphius Vaccines NV is a Belgian biopharmaceutical company that specializes in developing vaccines and therapeutics using its proprietary self-amplifying RNA and carrier technology platforms. The private company is based in Ghent, Belgium and has a portfolio of next-generation vaccine candidates that target infectious diseases and gene supplementation therapies. The company's lead compound, Zip1642, is a COVID-19 vaccine candidate that has undergone preclinical studies. The company was founded in 2019 by Christian Cardon, who has been the CEO since then. | Health Technology |
- Bourse
- Insiders
- Johan Van Hoof
- Expérience
